Advertisement

Topics

PubMed Journals Articles About "ERSPC European Randomized Study Screening Prostate Cancer" RSS

00:14 EST 19th December 2018 | BioPortfolio

ERSPC European Randomized Study Screening Prostate Cancer PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest ERSPC European Randomized Study Screening Prostate Cancer articles that have been published worldwide.

More Information about "ERSPC European Randomized Study Screening Prostate Cancer" on BioPortfolio

We have published hundreds of ERSPC European Randomized Study Screening Prostate Cancer news stories on BioPortfolio along with dozens of ERSPC European Randomized Study Screening Prostate Cancer Clinical Trials and PubMed Articles about ERSPC European Randomized Study Screening Prostate Cancer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ERSPC European Randomized Study Screening Prostate Cancer Companies in our database. You can also find out about relevant ERSPC European Randomized Study Screening Prostate Cancer Drugs and Medications on this site too.

Showing "ERSPC European Randomized Study Screening Prostate Cancer" PubMed Articles 1–25 of 78,000+

The Influence of decision aids on prostate cancer screening preferences: A randomized survey study.

Shared decision making is recommended regarding prostate cancer screening. Decision aids may facilitate this process; however, the impact of decision aids on screening preferences is poorly understood.


Predictors of participation in risk-based prostate cancer screening.

Implementation of risk-based prostate cancer screening has been proposed as a means to reduce the harms of PSA screening. Little is known, however, about the factors influencing men's decision to attend a prostate cancer screening based on a risk assessment.

Overdiagnosis in Colorectal Cancer Screening - Time to Acknowledge A Blind Spot.

Overdiagnosis is recognized as a major harm of mammography screening for breast cancer and prostate cancer screening with prostate-specific-antigen (PSA). Colorectal cancer screening is being more broadly implemented in many countries, and screening rates are increasing steadily. Surprisingly, there is a striking and almost complete lack of knowledge about overdiagnosis in colorectal cancer screening. Overdiagnosis is not part of patient information material, hardly mentioned in guidelines, and not addresse...


New Evidence for the Benefit of PSA Screening: Data From 400,887 Kaiser Permanente Patients.

To investigate whether prostate cancer screening with PSA is beneficial in reducing prostate cancer mortality, and to determine optimal screening intervals and age groups to be screened.

Personalized Prostate Cancer Screening Based on a Single Midlife Prostate-specific Antigen Measurement.

Breast cancer screening : present situation and prospects.

Breast cancer screening is a public health challenge. Belgium has the worldwide highest age-standardized breast cancer incidence. It ranks third in terms of specific mortality. The causes are unclear and presumably multifactorial. Like most European countries, Belgium has set up a screening program since 2001. Despite coverage rates varying from one Region to another, the annual 2 % specific mortality decline (observed in the vast majority of European countries) is the same. The age-based screening programs...

An Update on the European Lung Cancer Screening Trials and Comparison of Lung Cancer Screening Recommendations in Europe.

While lung cancer screening has been implemented in the United States, it is still under consideration in Europe. So far, lung cancer screening trials in Europe were not able to replicate the results of the National Lung Screening Trial, but they do show a stage shift in the lung cancers that were detected. While eagerly awaiting the final result of the only lung cancer screening trial with sufficient statistical power, the NELSON trial, a number of European countries and medical societies have published re...

A paradigm shift for prostate cancer diagnostics.

The current praxis of diagnosing prostate cancer, with systematic prostate biopsies in men with raised serum prostate-specific antigen (PSA) levels, leads to considerable over-diagnosis and over-treatment of indolent cancer. Recent research has opened up for a paradigm shift to risk stratified, sequential and targeted prostate cancer diagnostics, which will reduce over-diagnosis. Sweden now moves towards organised PSA testing for those men who, after proper counselling, wish to be tested. Organised PSA test...

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

We tested whether intervention with atorvastatin affects the prostate beneficially compared with placebo in men with prostate cancer in a randomized clinical trial. A total of 160 statin-naïve prostate cancer patients scheduled for radical prostatectomy were randomized to use 80mg atorvastatin or placebo daily from recruitment to surgery for a median of 27 d. Blinding was maintained throughout the trial. In total, 158 men completed the follow-up, with 96% compliance. Overall, atorvastatin did not significa...

Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer.

Prostate-specific antigen (PSA) is central in the diagnosis of prostate cancer. However, high-quality biological variation (BV) estimates for PSA are scarce. Here BV estimates from the European Biological Variation Study (EuBIVAS) for total (tPSA), free (fPSA), conjugated PSA (cPSA), and percent free PSA (%fPSA) are provided.

Mortality From Post-screening (Interval) Colorectal Cancers is Comparable to That From Cancer in Unscreened Patients-a Randomized Sigmoidoscopy Trial.

Endoscopic screening for colorectal cancer (CRC) is performed at longer time intervals than the fecal occult blood test or screens for breast or prostate cancer. This causes concerns about interval cancers, which have been proposed to progress more rapidly. We compared outcomes of patients with interval CRCs after sigmoidoscopy screening vs outcomes of patients with CRC who had not been screened.

The legal framework for European cervical cancer screening programmes.

A comprehensive legal framework needs to be developed to run the health services and to regulate the information systems required to manage and to ensure the quality of cancer screening programmes. The aim of our study was to document and to compare the status of legal basis for cervical screening registration in European countries.

The association between medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.

Despite the rapid diffusion of accountable care organizations (ACOs), the effect of ACO enrollment on cancer diagnosis, treatment, and survivorship remains unknown. The objective of this study was to determine whether Medicare Shared Savings Program (MSSP) ACO enrollment was associated with changes in screening for breast, colorectal, and prostate cancers.

Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population.

Prostate cancer is one of the most commonly diagnosed malignancies among men in Western populations. Evidence reported in the literature suggests that zinc may be related to prostate cancer. In this study we evaluated the association of serum zinc levels and polymorphisms in genes encoding zinc-dependent proteins with prostate cancer in Poland.

Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.

Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer. In the present study, we explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.

Three years of colorectal cancer screening in Denmark.

The Danish National Colorectal Cancer Screening Programme was implemented in March 2014 and is offered free of charge to all residents aged 50-74 years. The aim of this study is to compare performance indicators from the Danish National Colorectal Cancer Screening Programme to the recommendations from European Guidelines in order to assure the quality of the programme and to provide findings relevant to other population-based colorectal cancer screening programmes.

Energy Dispersive X-Ray Fluorescence Zn/Fe Ratiometric Determination of Zinc Levels in Expressed Prostatic Fluid: A Direct, Non-Invasive and Highly Accurate Screening for Prostate Cancer.

Prostate specific antigen (PSA) does not provide the reliability that is required for the accurate urology screening of prostate cancer (PCa). Consequently, there has been a major focus and search for a simple, rapid, direct, preferably non-invasive, and highly accurate biomarker and procedure for the urology screening for prostate cancer. Virtually all PCa cases exhibit a marked decrease in zinc in prostate tissue and in prostatic fluid. This is a hallmark "signature" clinical characteristic for all prosta...

Association between Trichomonas vaginalis and prostate cancer mortality.

We previously observed a positive association between seropositivity for the parasite Trichomonas vaginalis and risk of clinically significant prostate cancer at diagnosis. Here, we examined whether T. vaginalis seropositivity was associated with increased prostate cancer-specific or all-cause mortality among prostate cancer patients. We studied 749 men with prostate cancer from the Physicians' Health Study (PHS) and 736 men with prostate cancer from the Health Professionals Follow-Up Study (HPFS). We used ...

Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.

Experimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting.

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.

Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Therefore it is an appropriate target for diagnostic and therapy of prostate cancer and its metastases. This article discusses several articles on radionuclide treatments in prostate cancer and the results on PSMA therapy with either beta or alpha em...

Western Dietary Pattern, But not Mediterranean Dietary Pattern, Increases the Risk of Prostate Cancer.

Prostate cancer is the most common cancer among men. Several studies have investigated the effects of dietary patterns on prostate cancer risk, but this topic is still a matter of debate. This study aimed to examine the association between dietary patterns and prostate cancer risk.

Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.

To investigate if results in terms of absolute risk in mature randomized trials are relevant for contemporary decision making. To do so, we compared the outcome for men in the radical prostatectomy (RP) arm in the Scandinavian Prostate Cancer Group Study number 4 (SPCG-4) randomized trial with matched men treated in a contemporary era before and after compensation for the grade migration and grade inflation that have occurred since the 1980s.

The Role of Testosterone Therapy in the Setting of Prostate Cancer.

The role of testosterone in the development of prostate cancer and the safety of testosterone therapy (TTh) after prostate cancer treatment, or in the setting of active surveillance, remains controversial. There are many concerns about using TTh in men, particularly those with a history of prostate cancer, ranging from a possible increased risk of cardiovascular disease to cancer progression or recurrence. With many prostate cancer patients living longer, and hypogonadism having significant morbidity, much ...

Imaging the Human Prostate Gland Using 1-μm-Resolution Optical Coherence Tomography.

The accuracy of needle biopsy for the detection of prostate cancer is limited by well-known sampling errors. Thus, there is an unmet need for a microscopic screening tool that can screen large regions of the prostate comprehensively for cancer. Previous prostate imaging by optical coherence tomography (OCT) have had insufficient resolution for imaging cellular features related to prostate cancer. We have recently developed micro-optical coherence tomography (μOCT) that generates depth-resolved tissue image...

Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach.

Lung cancer is the leading cause of cancer death in Germany. Although several randomized trials in Europe have evaluated the effectiveness of lung cancer screening programs, evidence on the cost-effectiveness of lung cancer screening is scarce.


Advertisement
Quick Search
Advertisement
Advertisement